Literature DB >> 31403629

Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes.

Saahir Khan1, Aarti Jain2, Omid Taghavian2, Rie Nakajima2, Algis Jasinskas2, Medalyn Supnet2, Jiin Felgner2, Jenny Davies2, Rafael Ramiro de Assis2, Sharon Jan2, Joshua Obiero2, Erwin Strahsburger2, Egest J Pone2, Li Liang2, D Huw Davies2, Philip L Felgner3.   

Abstract

The influenza virus remains a significant cause of mortality worldwide due to the limited effectiveness of currently available vaccines. A key challenge to the development of universal influenza vaccines is high antigenic diversity resulting from antigenic drift. Overcoming this challenge requires novel research tools to measure the breadth of serum antibodies directed against many virus strains across different antigenic subtypes. Here, we present a protocol for analyzing the breadth of serum antibodies against diverse influenza virus strains using a protein microarray of influenza antigens. This influenza antigen microarray is constructed by printing purified hemagglutinin and neuraminidase antigens onto a nitrocellulose-coated membrane using a microarray printer. Human sera are incubated on the microarray to bind antibodies against the influenza antigens. Quantum-dot-conjugated secondary antibodies are used to simultaneously detect IgG and IgA antibodies binding to each antigen on the microarray. Quantitative antibody binding is measured as fluorescence intensity using a portable imager. Representative results are shown to demonstrate assay reproducibility in measuring subtype-specific and cross-reactive influenza antibodies in human sera. Compared to traditional methods such as ELISA, the influenza antigen microarray provides a high throughput multiplexed approach capable of testing hundreds of sera for multiple antibody isotypes against hundreds of antigens in a short time frame, and thus has applications in sero-surveillance and vaccine development. A limitation is the inability to distinguish binding antibodies from neutralizing antibodies.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31403629     DOI: 10.3791/59973

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  8 in total

1.  Analysis of SARS-CoV-2 antibodies in COVID-19 convalescent blood using a coronavirus antigen microarray.

Authors:  Rafael R de Assis; Aarti Jain; Rie Nakajima; Algis Jasinskas; Jiin Felgner; Joshua M Obiero; Philip J Norris; Mars Stone; Graham Simmons; Anil Bagri; Johannes Irsch; Martin Schreiber; Andreas Buser; Andreas Holbro; Manuel Battegay; Philip Hosimer; Charles Noesen; Oluwasanmi Adenaiye; Sheldon Tai; Filbert Hong; Donald K Milton; D Huw Davies; Paul Contestable; Laurence M Corash; Michael P Busch; Philip L Felgner; Saahir Khan
Journal:  Nat Commun       Date:  2021-01-04       Impact factor: 14.919

2.  Distinct SARS-CoV-2 antibody reactivity patterns in coronavirus convalescent plasma revealed by a coronavirus antigen microarray.

Authors:  Rafael Assis; Aarti Jain; Rie Nakajima; Algis Jasinskas; Saahir Khan; Huw Davies; Laurence Corash; Larry J Dumont; Kathleen Kelly; Graham Simmons; Mars Stone; Clara Di Germanio; Michael Busch; Philip L Felgner
Journal:  Sci Rep       Date:  2021-04-06       Impact factor: 4.379

3.  Estimated seroprevalence of SARS-CoV-2 antibodies among adults in Orange County, California.

Authors:  Tim A Bruckner; Daniel M Parker; Scott M Bartell; Veronica M Vieira; Saahir Khan; Andrew Noymer; Emily Drum; Bruce Albala; Matthew Zahn; Bernadette Boden-Albala
Journal:  Sci Rep       Date:  2021-02-04       Impact factor: 4.379

4.  A Novel Quantitative Multi-Component Serological Assay for SARS-CoV-2 Vaccine Evaluation.

Authors:  Morly Fisher; Alon Manor; Hagar Abramovitch; Ella Fatelevich; Yafa Afrimov; Gal Bilinsky; Edith Lupu; Amir Ben-Shmuel; Itai Glinert; Noa Madar-Balakirski; Hadar Marcus; Adva Mechaly
Journal:  Anal Chem       Date:  2022-03-01       Impact factor: 6.986

5.  Characterization of pathogen-inactivated COVID-19 convalescent plasma and responses in transfused patients.

Authors:  Maja Weisser; Nina Khanna; Anemone Hedstueck; Sarah Tschudin Sutter; Sandra Roesch; Gregor Stehle; Mihaela Sava; Nikolaus Deigendesch; Manuel Battegay; Laura Infanti; Andreas Holbro; Stefano Bassetti; Hans Pargger; Hans H Hirsch; Karoline Leuzinger; Laurent Kaiser; Diem-Lan Vu; Katharina Baur; Nadine Massaro; Michael Paul Busch; Graham Simmons; Mars Stone; Philip L Felgner; Rafael R de Assis; Saahir Khan; Cheng-Ting Tsai; Peter V Robinson; David Seftel; Johannes Irsch; Anil Bagri; Andreas S Buser; Laurence Corash
Journal:  Transfusion       Date:  2022-09-05       Impact factor: 3.337

6.  A Modular Microarray Imaging System for Highly Specific COVID-19 Antibody Testing.

Authors:  Per Niklas Hedde; Timothy J Abram; Aarti Jain; Rie Nakajima; Rafael Ramiro de Assis; Trevor Pearce; Algis Jasinskas; Melody N Toosky; Saahir Khan; Philip L Felgner; Enrico Gratton; Weian Zhao
Journal:  bioRxiv       Date:  2020-05-23

7.  Analysis of Serologic Cross-Reactivity Between Common Human Coronaviruses and SARS-CoV-2 Using Coronavirus Antigen Microarray.

Authors:  Saahir Khan; Rie Nakajima; Aarti Jain; Rafael Ramiro de Assis; Al Jasinskas; Joshua M Obiero; Oluwasanmi Adenaiye; Sheldon Tai; Filbert Hong; Donald K Milton; Huw Davies; Philip L Felgner
Journal:  bioRxiv       Date:  2020-03-25

8.  Administration of Multivalent Influenza Virus Recombinant Hemagglutinin Vaccine in Combination-Adjuvant Elicits Broad Reactivity Beyond the Vaccine Components.

Authors:  Jenny E Hernandez-Davies; Jiin Felgner; Shirin Strohmeier; Egest James Pone; Aarti Jain; Sharon Jan; Rie Nakajima; Algimantas Jasinskas; Erwin Strahsburger; Florian Krammer; Philip L Felgner; D Huw Davies
Journal:  Front Immunol       Date:  2021-07-14       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.